A Clinical Study in AGHD to Assess Safety, Tolerability and Efficacy of GX-H9

NCT02946606 | Completed Phase 2 DMC

• 1 other identifier: GX-H9-002
• Study Type: interventional
• Target: 45
• Locations: 1 country
• Sites: 1

Brief Summary

This is a randomized, active-controlled, open-label, sequential dose group, Phase 1b/2 study designed to assess the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of weekly and every other week doses of GX-H9 in the treatment of AGHD.

Conditions

Adult Growth Hormone Deficiency

Outcome Measures

Primary Outcomes (1)

• The change in insulin-like growth factor-1 (IGF-1) levels in relation to time and dose strength

  12 weeks

Secondary Outcomes (23)

• Pharmacokinetic (PK) profile of GX-H9 in the treatment of AGHD: Area under the curve, AUC0-t

  12 weeks

• PK profile of GX-H9 in the treatment of AGHD: Area under the curve, AUC0-inf

  12 weeks

• PK profile of GX-H9 in the treatment of AGHD: Area under the curve, AUC0-tau

  12 weeks

• PK profile of GX-H9 in the treatment of AGHD: Maximum serum concentration, Cmax

  12 weeks

• PK profile of GX-H9 in the treatment of AGHD: The time taken to reach the maximum concentration, Tmax

  12 weeks

Study Arms (3)

Group 1: GX-H9 + Genotropin

EXPERIMENTAL

GX-H9 (weekly dose), Genotropin (daily)

Drug: GX-H9; Drug: Genotropin

Group 2: GX-H9 + Genotropin

EXPERIMENTAL

GX-H9 (weekly dose), Genotropin (daily)

Drug: GX-H9; Drug: Genotropin

Group 3: GX-H9 + Genotropin

EXPERIMENTAL

GX-H9 (weekly dose), Genotropin (daily)

Drug: GX-H9; Drug: Genotropin

Interventions

GX-H9 DRUG

Human growth hormone

Group 1: GX-H9 + Genotropin; Group 2: GX-H9 + Genotropin; Group 3: GX-H9 + Genotropin

Genotropin DRUG

Human growth hormone

Group 1: GX-H9 + Genotropin; Group 2: GX-H9 + Genotropin; Group 3: GX-H9 + Genotropin

Eligibility Criteria

• Age: 20 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Each subject must meet all of the following criteria to be enrolled in this study:
• Is a male or female aged ≥20 and 65 years with AGHD, either adult onset GHD due to hypothalamic pituitary disease or childhood onset GHD that is either idiopathic or due to hypothalamic pituitary disease or due to genetic causes.
• Has documented confirmation (medical history) of GH deficiency during adulthood by 1 or more growth hormone (GH) stimulation tests, as follows:
• Insulin tolerance test (peak hGH≤3.0 ng/mL)
• Arginine + growth-hormone-releasing hormone (peak hGH≤4.0 ng/mL)
• Has been treated with stable hormonal replacement therapies for deficiencies of other hypothalamo pituitary axes and must have been on an optimized and stable treatment regimen for at least 3 months before screening (free thyroxine \[T4\] level within normal range at screening). Temporary adjustment of glucocorticoid replacement therapy, as appropriate, is acceptable.
• Has a screening IGF-1 level of at least 1 standard deviation (SD) score (IGF-1 SD score \<1) below the mean IGF-1 level standardized for age and gender according to the central laboratory reference values.
• Has a BMI of ≥18.0 and 35.0 kg/m2 (both male and female subjects).
• Has a confirmed negative test result for anti-recombinant human growth hormone (anti-rhGH) antibodies at screening.
• Must agree to use appropriate contraceptive methods (ie, condoms, cervical cap in conjunction with spermicide, sterilization, and intra uterine device) during the study and for 6 months after the last dose of study drug.
• Female subjects must have a negative serum pregnancy test result at screening.
• Must be willing and able to provide written informed consent before performing any study procedures.

You may not qualify if:

• A subject meeting any of the following criteria will be excluded from the study:
• Has evidence of growth of pituitary adenoma or other intracranial tumor within the last 12 months which has to be confirmed by computed tomography or magnetic resonance imaging scan (with contrast) within 3 months before screening. (Subjects with inactive remnant intracranial tumors are eligible).
• Is currently receiving antitumor therapy and has a history of malignancy other than i) cranial tumor or leukemia causing GHD, or ii) fully treated basal cell carcinoma or evidence of active malignancy.
• Has any clinically significant electrocardiogram (ECG) abnormality at screening.
• Has evidence of intracranial hypertension at screening.
• Has uncontrolled diabetes mellitus with diet and exercise, as determined based on glycated hemoglobin (HbA1c) levels ≥7.0% at screening.
• Has impaired liver function defined as elevation of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 2.0 × upper limit of normal (ULN).
• Has impaired kidney function defined as increased serum creatinine levels greater than 1.5 × ULN.
• Has had active acromegaly within 18 months before screening.
• Has active carpal tunnel syndrome.
• Has Prader-Willi syndrome.
• Has had active Cushing syndrome within 12 months before screening.
• Has any other major medical conditions, including eg, clinically manifested hypertension, tuberculosis, major surgery within the 3 months before screening, or significantly abnormal laboratory test results (eg, disturbed calcium homeostasis); or any other conditions (eg, acute infections) that may influence drug absorption, metabolism, or excretion, or that may interfere with any study variables in the judgment of the investigator.
• Has been treated with systemic corticosteroids other than replacement therapy within 3 months before screening.
• Is a female subject of childbearing potential who is pregnant, breastfeeding, or intends to become pregnant.

Sponsors & Collaborators

• Genexine, Inc.: lead

Study Sites (1)

Severance Hospital

Seoul, South Korea

Location

MeSH Terms

Conditions

Dwarfism, Pituitary

Interventions

GX-H9; Human Growth Hormone

Condition Hierarchy (Ancestors)

Dwarfism; Bone Diseases, Developmental; Bone Diseases; Musculoskeletal Diseases; Bone Diseases, Endocrine; Hypopituitarism; Pituitary Diseases; Hypothalamic Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Growth Hormone; Pituitary Hormones, Anterior; Pituitary Hormones; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Peptides; Amino Acids, Peptides, and Proteins

Study Officials

• Eun Jig Lee, MD, PhD

  Yonsei University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Masking Details: Open Label
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 28, 2015
• First Posted: October 27, 2016
• Study Start: January 1, 2015
• Primary Completion: December 30, 2016
• Study Completion: December 30, 2016
• Last Updated: September 7, 2017

Record last verified: 2017-09

Data Sharing

• IPD Sharing: Will not share

Locations

KR (1)